Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in South Korea / NCT02193464
Recruiting Observational

Inflammatory Bowel Disease Registry in Daegu-Gyeongbuk

NCT02193464 · tracked via the Priya Life Science South Korea tracker
Sponsor
Kyungpook National University Hospital
Phase
Observational
Started
2014-09
Last updated
2021-01-12

Condition(s) studied

Idiopathic Chronic Inflammatory Bowel Disease

Study summary

The purpose of this study is to investigate the incidence and natural course of inflammatory bowel disease in the southeastern area of Korea.

Eligibility

Sex
ALL
Min age
—
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Clinical diagnosis of inflammatory bowel disease including Crohn's disease and ulcerative colitis * Followed up for at least 6 months for the correct diagnosis Exclusion Criteria: * Patients who do not live in Daegu-Gyeongbuk province

Primary outcome measure(s)

  • All newly diagnosed cases — one year
    In one year, all inflammatory bowel disease including Crohn's disease and ulcerative colitis which is newly diagnosed in Daegu-Gyeongbuk province of Korea is recorded.

Trial sites (1)

FacilityCityRegionStatus
Keimyung University Dongsan Medical Center Daegu South Korea Recruiting

More Kyungpook National University Hospital trials in South Korea

The Treatment Effect for Asymptomatic Common Bile Duct Stone Recruiting
Early Commencement of Adjuvant Chemotherapy for Colon Cancer Active, not recruiting
Neoadjuvant FOLFOX Chemotherapy for Patients With Locally Advanced Colon Cancer Active, not recruiting
Analysis of Biomarkers From Patients With Chorioretinal Diseases Recruiting
Preoperative Sequential Short-course Radiation Therapy and FOLFOX for Locally Advanced Rectal Cancer Active, not recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT02193464 on ClinicalTrials.gov ↗ ← All trials in South Korea